Klaus Stoeckemann is a co-founder and Managing Partner of Peppermint VenturePartners (PVP). PVP focuses on investments in medical device and digital-health start-up companies in Germany and Europe.

As a former General Partner in the 3i Healthcare Venture Capital team, he is a highly experienced venture capitalist with more than 16 years of experience in this industry. Before that he worked in different leading positions at Schering AG (now Bayer) and Asta Medica (Degussa). He was responsible for more than 12 investments and exits during his tenure at 3i. His track record includes the IPOs of companies such as for example Epigenomics and Jerini, as well as the trade sales of Evotec Neuroscience, Amaxa and Elbion.

Klaus has been board member of Combinature, Epigenomics, Jerini, Amaxa, Immatics as well as IntelliDx and Zonare in the US. He is currently chairman of the boards of Emperra as well as Caterna Vision and board member of Implandata and Humedics and focuses on digital health and medical device investments across Europe. In addition he is mentor at the first vertical medical accelerator eyefocus based in Berlin which PVP also supports and jury member of the Helmholtz Enterprise Fund. In June 2015 he became member of the board of the German Association of Venture Capital (BVK).

Klaus holds a PhD in Biology and Pharmacology from the University of Mainz as well as a MBA from WHU / Kellogg Northwestern University in the US.